Two Hong Kong residents are in serious condition after receiving China’s Sinovac COVID-19 vaccines, the Hong Kong government announced on Sunday, after a 55-year-old woman with chronic illness died four days after receiving her vaccine—the second related death in the city.
The health department has said that the mild conditions were caused by the vaccine, while the cause of the deaths and serious reactions were still unclear.
2 DeathsThe Hong Kong Health Department confirmed on Saturday that the second death, the 55-year-old woman, was due to an acute stroke on Friday.
According to the department, the woman had a history of high blood pressure, high blood lipids, and proteinuria, but still could work.
On March 2, the woman received the first dose of CoronaVac at a local community vaccination center. At 7:00 p.m. on Friday, she was working her usual job when she lost control over the left side of her body. She was rushed to hospital by ambulance and diagnosed with a stroke. She passed away at 4:51 a.m. on Saturday morning.
It’s unclear whether the vaccine contributed to the woman’s death. The authorities said they would perform an autopsy and investigate the cause of death.
2 in Serious ConditionThe first ICU case is an 80-year-old man who has a history of diabetes, carotid atherosclerosis, hypertension, and stroke. He received the vaccine on Monday and called for an ambulance on Saturday due to chest pain. He was in a very serious condition on Sunday after not responding well to treatment, according to the department.
The second ICU case is a 72-year-old woman, who also has a history of diabetes, hyperlipidaemia, hypertension, and hypothyroidism. She received the vaccine on Saturday but skipped two doses of insulin that she took every day when she felt unwell after the vaccination. When her condition declined Sunday morning, her family sent her to the hospital where they found she had severe diabetic ketoacidosis.
SinovacChinese authorities have approved three types of COVID-19 vaccines for emergency use, which include CoronaVac and two inactivated virus vaccines from Sinopharm, but only for people aged 18 to 59, saying that “other age groups need to wait for the vaccines’ further clinical trials.”
However, the Hong Kong government approved CoronaVac and suggested that seniors be vaccinated.
Vaccinations in Hong KongHong Kong administrations have only approved three types of vaccines for emergency use: Chinese company Sinovac’s CoronaVac, Chinese partner of Pfizer Fosun Pharma and Germany company BioNTech’s Comirnaty, and a single-dose Oxford-AstraZeneca vaccine.
The government started to vaccinate its people on Feb. 22. Nobody has had the chance to receive their second dose since they need to wait about 28 days.
Due to the shipment schedule, the majority of vaccines that Hongkongers have received are supplied by Sinovac.